[ad_1]
WHO Director-General Dr. Tedros Adhanom Ghebreyesus organized the first of the weekly videoconferencing press conferences at the organization’s headquarters in Geneva, Switzerland.
Expressing his satisfaction with the positive news from the studies of the Kovid-19 vaccine, Ghebreyesus cautioned that the speed shown in the development of the vaccines must also be shown in terms of their fair distribution.
Ghebreyesus emphasized that no such rapid vaccine has been developed against any epidemic in history, “With the latest positive news from vaccine trials, the light at the end of this long, dark channel (tunnel) is getting brighter. Currently , vaccines with other tried and tested public health measures. ” There is real hope that it will help end the epidemic. ”The evaluation found.
Stating that scientists have reached a new standard in vaccine development, Ghebreyesus said: “The international community now has to set a new standard of access (for vaccines).” said.
“WE HAVE TO WAIT FOR THE ASTRAZENECA VACCINE”
Answering the question on vaccination studies, Senior Expert from the WHO Scientific Delegation. Soumya Swaminathan spoke cautiously about the candidate vaccine Kovid-19 developed by the University of Oxford in cooperation with the British-Swedish pharmaceutical company AstraZeneca.
After stating that he was aware of claims that the vaccine in question was effective at a level of 70 percent if given in a single dose, the first half of the dose, and then 90 percent if given, Swaminathan said : “I think we should wait to see the efficacy and safety results. He used the expressions.
Recalling that the AstraZeneca vaccine is currently being tested in 60,000 people in many other countries, Swaminathan noted that they should await future test results to “make more informed decisions.”
BIONTECH AND PFIZER 95 PERCENT COLLECTIVE VACCINE EFFECTIVE
class = “cf”>
Prof. Dr. Uğur Şahin and Dr. The official application was made to the United States Food and Drug Administration (FDA) on November 20 for the emergency use of the coronavirus vaccine produced by the German company BioNTech, which It is managed by the Özlem Türeci couple, with the US pharmaceutical giant Pfizer.
The application to the US Drug Administration is based on the results of phase 3 clinical trials of the vaccine. Vaccine trials began in the US on July 27, and more than 43,000 people were tested in the process.
class = “cf”>
Based on the final analysis obtained from the tests, the BioNTech / Pfizer vaccine was 95 percent effective in preventing coronavirus. The vaccine is also effective in the elderly and has no serious side effects.
It was stated that in the phase 3 vaccine trials, 42 percent of global participants from diverse backgrounds and 30 percent of participants from the United States participated in caring for race and ethnicity.
